---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290460006.md"
description: "MapLight Therapeutics shares are trading higher after the company announced topline results from IRIS (ML-004-002), a Phase 2 study of ML-004 in autism spectrum disorder."
datetime: "2026-06-22T15:44:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290460006.md)
  - [en](https://longbridge.com/en/news/290460006.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290460006.md)
---

# 

MapLight Therapeutics shares are trading higher after the company announced topline results from IRIS (ML-004-002), a Phase 2 study of ML-004 in autism spectrum disorder.

### Related Stocks

- [MPLT.US](https://longbridge.com/en/quote/MPLT.US.md)

## Related News & Research

- [MapLight says Phase 2 ZEPHYR trial shows ML-007C-MA cuts PANSS score in schizophrenia](https://longbridge.com/en/news/293920685.md)
- [Maplight Therapeutics (NASDAQ:MPLT) Director Acquires $148,702.40 in Stock](https://longbridge.com/en/news/294144422.md)
- [MapLight Therapeutics, Inc. (MPLT) Gets a Buy from Jefferies](https://longbridge.com/en/news/294388175.md)
- [Biointron introduces RushData platform for AI-driven antibody discovery](https://longbridge.com/en/news/293919988.md)
- [ProQR Therapeutics (PRQR) to Announce Earnings on Thursday](https://longbridge.com/en/news/294355448.md)